# Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

> **NCT03955783** · PHASE1 · COMPLETED · sponsor: **Sanjay Mohan** · enrollment: 78 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Acute Myeloid Leukemia
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Selinexor

## Key facts

- **NCT ID:** NCT03955783
- **Lead sponsor:** Sanjay Mohan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-21
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2024-10-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03955783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03955783, "Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03955783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*